Scarica l'app Stockscreener
4.3601
1.13%
-0.0499
An 2 Therapeutics Inc Borsa (ANTX) Ultime notizie
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) - Yahoo Finance UK
Form 4 Lineage Cell Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - BioSpace
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress - Business Wire
Kymera Therapeutics (KYMR) Extends Rally On Sanofi Milestone And Lupus Data - StocksToTrade
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.15, Implies 2% Downside - TradingView
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st
SYRE Stock Climbs As TL1A Data Ignite Analyst Upgrades - StocksToTrade
APGE Stock Climbs As Street Backs Zumilokibart Momentum - StocksToTrade
Allarity Therapeutics to Present Trial-in-Progress Poster - GlobeNewswire
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - PR Newswire
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P - GlobeNewswire
Elicio (Nasdaq: ELTX) Phase 2 ELI-002 refocuses on R0 patients - Stock Titan
Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise - StocksToTrade
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom - GlobeNewswire
TGTX Stock Surges As Briumvi Pipeline Momentum Accelerates - StocksToTrade
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients - GlobeNewswire
TG Therapeutics Announces Positive Topline Phase 1 Data for - GlobeNewswire
Tango Therapeutics Announces Combination of Vopimetostat - GlobeNewswire
Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron - Yahoo Finance
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease - Business Wire
Tenaya to unveil TN-201 gene therapy HCM trial data June 3, 2026 - Stock Titan
Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Business Wire
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - Business Wire
Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting - Business Wire
Monopar Therapeutics Presents Phase 2 Data for ALXN1840 at EASL Congress 2026, Demonstrating Liver Disease Stabilization and Neurological Improvements in Wilson Disease Patients - Quiver Quantitative
Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease - PR Newswire
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic DermatitisSlideshow (NASDAQ:APGE) 2026-05-30 - Seeking Alpha
Monopar Therapeutics (MNPR) shares Phase 2 Wilson disease data at EASL 2026 - Stock Titan
C4 Therapeutics, Inc. unveils Phase 2 trial progress for cemsidomide at ASCO26 - Traders Union
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - PR Newswire
Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout - PR Newswire
This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday - Benzinga
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting - BioSpace
Black Diamond Therapeutics Announces Positive Phase 2 - GlobeNewswire
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - Business Wire
Relay Therapeutics (Nasdaq: RLAY) shares early zovegalisib vascular anomaly data - Stock Titan
Amplexd Therapeutics Initiates Phase 2 Clinical Trial of Investigational EGCg-Based HPV Therapy - GlobeNewswire
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - GlobeNewswire
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVCSlideshow (NASDAQ:TNYA) 2026-05-17 - Seeking Alpha
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology - Yahoo Finance
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $26, Implies 2% Upside - TradingView
Encoded Therapeutics Presents New Clinical Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the ASGCT 2026 Presidential Symposium - Business Wire
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 - PR Newswire
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewswire
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-05-09 - Seeking Alpha
Millennium-linked entities file 13G/A for Tenax Therapeutics (NASDAQ: TENX) reporting ~2% stakes - Stock Titan
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Avalo Therapeutics (AVTX) jumps as Phase 2 LOTUS topline results and $375M financing reshape outlook - Quiver Quantitative
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease - Business Wire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas - Yahoo Finance
MapLight Therapeutics Completes Enrollment in ZEPHYR Phase 2 Trial for Schizophrenia and Final Patient Visit in IRIS Phase 2 Trial for Autism Spectrum Disorder - Quiver Quantitative
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with - GlobeNewswire
Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study - Yahoo Finance
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026 - GlobeNewswire
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer - Investing News Network
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Yahoo Finance
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M - GlobeNewswire
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer - GlobeNewswire
Spotlighting Abeona Therapeutics And 2 More High Growth Stocks Insiders Favor - Yahoo Finance
Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting - Business Wire
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - GlobeNewswire
Black Diamond Therapeutics Announces Oral Presentation of - GlobeNewswire
1.95%
2.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):